CA 125 is a protein marker often measured in blood tests to monitor certain cancers, including endometrial and ovarian types. A normal CA 125 level is generally below 35 U/mL, though this threshold varies slightly between labs. Elevated levels do not confirm endometrial cancer but may signal the need for further evaluation.
CA 125 is produced by epithelial cells lining the reproductive organs. While it's most closely associated with ovarian cancer, it can also rise in endometrial cancer due to tumor shedding into the bloodstream. However, it is not a standalone diagnostic tool. Levels above 35 U/mL occur in approximately 20-30% of early-stage endometrial cancers and up to 60% in advanced cases, according to the American Cancer Society.
Normal CA 125 values do not rule out endometrial cancer. About 70% of women with early-stage endometrial cancer have levels within the normal range. This means a negative result cannot exclude malignancy. Conversely, elevated CA 125 may stem from benign conditions such as endometriosis, pelvic inflammatory disease, or even menstruation, which affects up to 15% of healthy women.
CA 125 functions as a tumor marker, not a screening test. It reflects biological activity rather than confirming cancer presence. Clinicians use serial measurements-tracking changes over time-to assess treatment response or disease recurrence. A rising trend over weeks or months is more meaningful than a single value.
For example, a woman diagnosed with stage II endometrial adenocarcinoma had a baseline CA 125 of 28 U/mL. After surgery and chemotherapy, her level dropped to 12 U/mL. Six months later, it rose to 41 U/mL. This increase prompted imaging, revealing a recurrent lesion in the pelvis. Treatment was adjusted accordingly. This illustrates how CA 125 supports clinical decisions, not replaces them.
CA 125 is not useful for initial diagnosis. The National Complete Cancer Network (NCCN) guidelines state that CA 125 should not be used to screen asymptomatic women due to low specificity and high false-positive rates. Instead, it's reserved for monitoring known disease or evaluating abnormal uterine bleeding when imaging is inconclusive.
CA 125 is a glycoprotein derived from the MUC16 gene. It binds to mucin-like molecules on the surface of epithelial cells in the fallopian tubes, ovaries, and endometrium. When these cells shed tumor fragments into circulation, CA 125 enters the bloodstream. Levels correlate with tumor burden in many cases, but not all.
Non-cancerous conditions can improve CA 125. A 2021 study in JAMA Oncology found that 12% of women with benign gynecologic disorders had levels above 35 U/mL. Conditions like liver cirrhosis, pregnancy, and chronic inflammation also contribute. Even benign ovarian cysts can raise levels moderately.
Some patients with endometrial cancer show no elevation despite advanced disease. A 2019 retrospective analysis in Gynecologic Oncology reported that 28% of women with grade 3 endometrioid carcinomas had normal CA 125 levels at diagnosis. This underscores the limitations of relying solely on biomarkers.
Many assume CA 125 is specific to ovarian cancer. That's incorrect. While it's most sensitive for high-grade serous ovarian carcinoma, it lacks specificity. Over 50% of endometrial cancers do not trigger significant elevations. Using CA 125 as a primary screening tool leads to unnecessary biopsies and anxiety.
Another misconception is that a normal CA 125 guarantees absence of cancer. This is false. A 2020 study in The Lancet Oncology showed that 33% of women with stage I endometrial cancer had levels under 35 U/mL. Relying on a single test value risks missing early disease.
CA 125 levels fluctuate naturally. Hormonal shifts during the menstrual cycle can cause transient increases. One patient had a level of 42 U/mL during ovulation, dropping to 26 U/mL two weeks later. Repeat testing confirmed the initial rise was physiological, not pathological.
| Condition | Typical CA 125 Range (U/mL) | Prevalence of Elevation (>35 U/mL) |
|---|---|---|
| Endometrial cancer (all stages) | 10-150 | 20-60% |
| Ovarian cancer (high-grade serous) | 20->1000 | 80-90% |
| Endometriosis | 15-100 | 30-40% |
| Pelvic inflammatory disease | 10-80 | 25% |
| Healthy premenopausal women | 5-35 | 5-10% |
These ranges show that CA 125 is not diagnostic. A value above 35 U/mL suggests further investigation but does not confirm cancer. The same applies to values below 35 U/mL-normal levels don't eliminate concern.
A 58-year-old woman presented with postmenopausal bleeding. Transvaginal ultrasound revealed a 2.8 cm endometrial polyp. Her CA 125 was 32 U/mL-within normal limits. Endometrial biopsy confirmed endometrioid adenocarcinoma, grade 1. She underwent hysterectomy and bilateral salpingo-oophorectomy. Post-op CA 125 dropped to 18 U/mL.
Her normal CA 125 did not delay diagnosis. The bleeding and imaging were the drivers. This case shows that CA 125 is supplemental, not primary. Relying on it alone would have missed the cancer.
I've seen multiple patients with normal CA 125 levels who later developed metastatic disease. One had a level of 29 U/mL at diagnosis. Within 18 months, she developed liver metastases. Her CA 125 rose to 180 U/mL. This pattern reinforces that CA 125 tracks disease progression, not initial detection.
CA 125 normal range for endometrial cancer is below 35 U/mL, but this does not rule out disease. Elevated levels may reflect benign conditions. The test is not used for screening or diagnosis. It supports monitoring in known cases.
When CA 125 is elevated, clinicians consider imaging, biopsy, and histopathology-not the marker alone. For women with symptoms or risk factors, CA 125 should be interpreted alongside clinical findings.